### **Funding Your Innovation:** Capital Options; Equity Economics; Working with Investors

University of San Diego, MRH Warren Auditorium September 21, 2018; San Diego, California

# Old Habits

Disrupting

#### Martin Kleckner III PhD MBA



© MKleckner 2018







**From Their Perspectives** 



### **3rd of a Four-Part Series**

#### July 12, 2018: SBIR STTR – The Basics

August 23, 2018: SBIR/STTR Phase II – Beyond the Basics

**September 21, 2018: Funding Your Innovation:** SBIR Phase I & II Grants, SBIR Phase III Support, Business Alliances, Private Equity; Corporate Funding; Term Sheet – Economics & Control Parameters; Capitalization Table

October 18, 2018: Roadmap to Commercialization





### Some Other Time

#### Addendum

- I "Crossing the Chasm"
- II "Investor Pitch Academy"
- III Overviews
  - The Term Sheet:
    - (a) Economic, (b) Control
  - Capitalization Table
  - Convertible Debt
- IV Telling Our Story

### Where I'm Coming From


- 1) Six Launches; Two Exits
  - RegeneMed
  - InSilicoMed
  - SpyFinder (Sold)
  - Sal-Flex (Sold)
  - + RefluxMD, U P Labs




Adjunct Faculty/Advisor: University of Southern California, California Institute of Technology, U C Irvine, Georgia Tech, U C Riverside, Ohio State, SDSU, CSU Fullerton


- 2) Not-For-Profit 501 (c) 3 pediatric cancer research institute
- 3) SBIR/STTR: NSF, NIH, DoD, DOE, DOT, DoEd, USDA, Coulter, Drexel; University of California; Cal State; L. A. BioMed Research Institute
- 4) General Electric, Roche, Toshiba; Honeywell (Europe, Asia, Americas)
- 5) \$39.5 MM in Capital & Grants Q2 2016 Q2 2018
- 6) Tech Innovation & Commercialization (BRINK) Univ of San Diego

### What is Your Odyssey?



### **Setting The Stage**






https://www.fundivo.com/stats/angel-investment-statistics/


### Influencing Buyer Behavior

#### **People Buy Emotionally, Rationalize Later**



#### How (Customer) Decisions Are Made

#### People Buy Emotionally, Rationalize Later




#### How Well Do You Understand (Know) Me?

- 1) Decisions often occur in this precise, psychological order
  - About us
  - About our company
  - About our product or service
  - About our ask/price
  - About the time to invest/buy
- 2) Two Key Issues: (a) Our Integrity, (b) Our Judgment [aka: Us]
  - How well does our product knowledge match our understanding of their needs?
  - WE . . . Will Be Assessed
- 3) Most importantly: About Themselves

#### How (Investor) Decisions Are Made

#### **People Buy Emotionally, Rationalize Later**




#### How Well Do We Understand (Know) Them?

- 1) Decisions often occur in this precise, psychological order
  - About us
  - About our company
  - About our venture/innovation
  - About our ask/price
  - About the time to invest/buy
- 2) Two Key Issues: (a) Our Background,(b) Our Capabilities [aka: Us]
  - How well does our background match our understanding of their decision criteria?
  - WE ... Will Be Assessed

3) Most importantly: Their Interests

#### How (Investor) Decisions Are Made

#### **People Buy Emotionally, Rationalize Later**



#### How Well Do We Understand (know) Them?

- 1) Decisions often occur in this precise, psychological order
  - About us
  - About our company
  - About our Evidence (Proof)
  - About our Traction
  - About the time to invest/buy
- 2) Three Key Issues: (a) Our Integrity, (b) How We Think, (c) Communicate/Listen
  - How well does our background match our understanding of their decision criteria?
  - WE . . . Will Be Assessed

3) Most importantly: Their Interests

We're turning the industry upside down


### So, How Should We Position Ourselves?

### Why Do Start-Ups Fail?

- \*\*\*

- **1**1

### Why Do Start-Ups Fail?



Fortune.com/2014/09/25/why-startups-fail-according -to-their founders/



Fortune.com/2014/09/25/why-startups-fail-according -to-their founders/

### More startups fail from a lack of customers than from a failure of product development

### **Investor Questions**

1) What is our Business Model?

- 2) How did our Model come about?
- 3) What Traction have we gained?



ational Institute of Health





### This is True for SBIR Funding as Well: Criteria for Investment



Significance
 Innovation

3. Approach
 4. Investigators
 5. Environment

6. Overall Impact

#### NIH Reviewer "Marching Orders"

Title Abstract Problem Solution Specific Aims Research Strategy Facilities Biographies



### **Focus: Key Criteria**

## Intellectual Merit Impact on Society



1. Advance Knowledge and Understanding

2. Benefit Society

 Creative, Original, Innovative, Transformative
 Well-reasoned; well organized; sound rationale; mechanism to assess success
 Your Qualifications

### **DOE External Peer Review: CRITERIA**





- At least 3 technical reviewers
- 1 reviewer for the Phase II
   Commercialization Plan
- Review Criteria (equally weighted)
  - 1) Strength of the Scientific/Technical Approach
  - 2) Ability to Carry Out the Project Cost Effectively

Panel Composition/Affiliation:

- 1) National Laboratory (49%)
- 2) University (32%)
- 3) Government (10%)
- 4) Private Sector (9%)



### **DoD Evaluation Factors**

- 1) Military & Program Relevance
- 2) Research Objectives
- 3) Scientific Excellence
- 4) Impact/Outcomes
- 5) PI & Key Personnel Qualifications
- 6) Facilities
- 7) Budget

8) Commercialization Strategy

Source Selection Authority & selected team; specified factors noted in Program Solicitation; includes performance history.

SBIR/STTR Desk Reference: "Evaluation & Selection"-(http://www.acq.osd.mil/osbp/sbir/sb/res ources/deskreference/02\_eval.shtml)



### **Beyond Technology: Market Buy-In**







Impact

Significance Innovation Approach Investigators Environment Impact





Relevance **Intellectual Merit** Objectives Impact/Benefit Scientific Excellence Advance Knowledge Impact Creative, Original, Qualifications Transformative Facilities Well-Reasoned Budget Qualifications Commercialization Resources

### **REJECTED?**



#### **Common Problems**

- 1) "They Don't Get It"
- 2) Problem Is Not Significant (Enough)
- 3) Not Innovative
- 4) We're Not Qualified
- 5) Flawed Study Approach

### **Common Problems**

#### 1) Our Proposal Is NOT CLEARLY WRITTEN

Use peer review to improve solution and pitch

#### 2) Our Proposal is NOT INNOVATIVE

- NOT CLEARLY DIFFERENTIATED: Position Technology Solution Relative to Current Standard & Alternative Solutions/Offering Being Developed
- NOVEL COMBINATION Of Existing Approaches: Emphasize Novelty AND Clinical Need

#### 3) Team is NOT QUALIFIED

- Add collaborators and consultants
- Create a Multi-PI Group (To Address Experience Issues)

### **More Common Problems**

#### 4) We're Not Working on a SIGNIFICANT PROBLEM

- Sell on Problem Importance: Repercussions/Ramifications
- Be More Specific and Quantitative
- Get Letters of Support in re Problem and Buyers/End Users

#### 5) Reviewers Are Critical of OUR APPROACH

- Respond to Their Criticisms
- Revise the Approach
- Have Others Review and Critique Approach

### "Deal Killers" for Some

Specific Aims

**Research Question** 

[Literature, Pertinent Work to Date, ...]

Study Approach

Purpose or Hypothesis

[Predictions, Variable Relationships, Cause & Effect, Possible Explanation(s) . . .]

[What is Measured, How, Controls, How Data Interpreted]

### Why 65% of SBIRs are Partnerships

#### Study Design

e.g. Single/Double Blind Study Population Sample Size/Power Anal. Outcomes/Endpoints



#### **Study Procedure**

e.g. Sampling Plan, Criteria Recruitment Procedure Screening Randomization (if applicable) Study Intervention Assessments & Activities

Analysis Plan Statistical Methods Background



#### ... For Financial and Strategic Investors (Steps 2 & 3):

- 1) Proof of Concept, Feasibility (SBIR/STTR Phase I)
- 2) Proof of Efficacy (SBIR/STTR Phase II) & Market
- 3) Evidenced-Based Commercial Traction (Phase III) [Business Model • How Generated • Traction]



#### **Congressional Emphasis: Commercialization**

#### Reauthorization Act of 2011

- 1) More Emphasis on Commercialization
- 2) Requirements
  - SBC Applicant Registers at SBIR.gov (Commercialization Database)
  - Phase II Awardee Commercialization History
  - Phase II Commercialization Process
  - Phase III Acquisition Preference
- 3) Added Agency Flexibility
  - VC/HF/PEF Ownership Stakes
  - Commercialization Assistance programs
  - Option for Non-Agency Commercialization Support

#### "Can Our Dog Hunt?"

- 1) Our Past Record
- 2) Phase II Support Commitments
- 3) Phase III Funding Commitments
- 4) Phase I Performance

In- Large Part: How We Are Considered for SBIR Phase II



## **Commercialization Plans**

Agency	Phase I	Phase II			
NIH/HHS	<sup>1</sup> ⁄2 page	12 Pages			
DOE	3 - 5 Pages 15 F				
NSF	6 – 8 Pages 15 Pa				
USDA (SBIR-Only)	1 Page +/-	10 Pages			

## **Commercialization Support**

- I. NIH: Phase I "Technology Niche Analysis" (TNA)
- **II. NIH, NSF: Commercialization Assistance Program** (Phase II)
- III. The I-Corps Program Innovation & Technology Commercialization Methodology ("Lean Launch Pad")
  - The Business Model Canvas
  - The Customer Discovery & Validation Process
  - Supplemental, Special (e.g. Matching Funds)
- **IV.** DOE, DOT: Commercialization Assistance Program

#### **NIH Phase I Awardees:** [Foresight Science & Technology]



- Technology Niche Analysis<sup>®</sup> (TNA)
- Commercialization Plan
- Go/No-Go<sup>®</sup> Assessment Report
- JumpStart<sup>™</sup>
- Market Overview
- Royalty Rate Analysis

#### CAP for Phase II Awardees (NIH) (https://sbir.nih.gov/cap#cap-home)

Managed through a contract with <u>Larta</u> (www.larta.org) of Los Angeles, CA individual mentoring and consulting sessions, training workshops, access to domain experts



- 1) Commercialization Training Track (CTT)
- 2) Accelerated Commercialization Training Track (ACT)
- 3) Regulatory Training Track (RTT)

## DAWNBREAKER® S DAWNBREAKER'

#### Phase I Awardees

- Kickoff Webinar
- Commercialization Readiness Assessment (CRA)
- Market Research
- Specialty Webinars
- Business Mentoring: Phase II Commercialization Plan
- Road Tours (e.g. UCSD, UC Irvine, UCLA last year) + National)

www.dawnbreaker.com <u>http://science.energy.gov/sbir/commercialization-assistance/</u>

#### Phase II Match Funding (NSF "Phase IIB")



- Aim: Extend R & D Efforts Beyond Current P-II Grant
- Further Accelerate Commercialization
- 50% of 3<sup>rd</sup> Party Investment Funds Up To \$500,000
- Must Start Process At least 30 Days Prior to Phase II Award Expiration; Investment Minimum of \$100K
- (See: https:// www.nsf.gov/eng/iip/sbir/Supplement)

### **Comm./Strat. Partnerships**

- NSF: "Technology Enhancement for Commercial Partnerships"
- Funding for additional research that goes beyond the Phase II project's objectives to meet technical specifications or additional proof-of-concept requirements. (Submit w/in 18 months of PII award)
- Additional research to enhance the commercial potential and lead to partnerships with industrial partners & secure venture/angel investors.
- Max Funding: 20% of the Phase II award, up to \$150,000
- Pre-submission Executive Summary + Letter from Commercial Partner

(Reference: www.nsf.gov/eng/iip/sbir/Supplement/instructions.jsp)



#### **Commercialization Assistance**

- Funding to secure the services of a third-party service provider to assist in commercialization
- Max Funding: \$10,000 per Phase II award (one per active Phase II grant)
- Deadline: Within 12 months of the effective start date of Phase II award (*recommended*)

https://www.nsf.gov/pubs/2014/nsf14072/nsf14072.pdf



## Often, our Commercialization Plan (for Phase II funding) is not well written.


#### SBIR · STTR America's Seed Fund





National Institutes of Health







#### **National Cohorts**

> CUSTOMER CREATION COMPANY BUILDING (USTOMER) T PIVOT EXECUTION SEARCH

## Seven (7) Week Curriculum (Agency Grant-Funded: \$40K - \$70K)

- Precursor Competitive Programs
  - e.g. "IN-LA" "Zap" & "Boom" (USC, UCLA, Caltech)
  - e.g. SDSU (Cal State system) CSUPERB BIO 2018 I-Corps
  - (May require SBIR Phase-I Award to get in)
- 3 5 + Week Site-Based Programs (UCI, UCR, UCSD et al.)

### How do Early Stage Angels relate?

# **Investor Questions (Again)**

1) What is your Business Model?

- 2) How did your Model come about?
- 3) What Traction have you gained?

# What About My Business Plan?

## What We Used to Believe

#### **Start With a Business Plan and Financial Model**

## EVERYONE has a plan until they get **PUNCHED IN** THE MOUTH.

## No battle plan survives first contact with the enemy.


- Helmuth von Moltke<sup>1</sup>

No Business Plan survives first contact w/ customers. - Steve Blank<sup>2</sup>

We haven't read a business plan in over twenty years. - Brad Feld/Jason Mendelson<sup>3</sup>



(1) 19th-century head of the Prussian army; (2) Stanford & UC Berkeley (I-Corps); (3) Foundry Group, Boulder, CO



	Charles and	ALBIC	0 1	1.1	11	1		L 1	F.F.	11
	a Bal	ance Sheet						Year		
	38					1999	2000	2001	2002	2
	34 Asse	15								
	35	Cath and cath equival	ents"			54.27	\$6.38	\$7.62	58.83	3
	30	Accounts receivable*				\$20.54	\$24.32	528.77	584.11	- 53
BUSINES	37	Inventories"				\$26.73	\$39.45	336.75	\$43.27	53
DAQUITEA	38	Deferred income taxe	5*			50.08	58.80	50.00	50.00	4
	79	Total current assets				331.54	561.22	\$78.14	\$46.21	- 57
PLAN	40	Friced assets								
a material	-41	Cost*				5381.64	\$423,92	2343.47	5543.24	- 545
	44	Accumulat	ed Depraination*			298,72	5105.09	5112-40	5122.26	- 511
	41	Netfixeda	129451			\$232.92	5314.83	\$3191.47	\$491.02	333
Preparted by: Olaon & Azocdaties R.O. Bace2240 Friederick, MD 21 T05 [201] 1005-2500	-44	Goodwill*				30.00	50,00	\$0,00	\$0.00	-
	-45	intingible assets."				50.00	\$0.98	50.00	50.08	
	48	Other all ints"				50.08	50.00	56.00	50.08	- 3
	43	Total assets				\$284.50	\$580.85	\$484.61	\$577.23	562
	48 Linb	lities								
	-29	Accounts puryable*				\$31.83	583.43	\$33.84	584.41	- 5
	54	Current risht*				530.84	\$43.88	\$64.85	\$79.49	
	51	Total current liabilitie	1			562.69	5106.46	\$148.65	5173.90	5
	52	Long-term debt*				\$46.00	544,52	353.41	\$78.57	5.0
	51	Other long-term lishil	ities"			50.68	59.80	50.00	59.08	1
	54	Total liabilities				\$102.69	\$153.38	\$292.10	5247.47	5.2
	55 Shue	eholders' equity								
	20	Common Stock and As	iditional Paid in Cap	itial *		590.00	\$153,90	\$150.00	5229.00	529
	57	Retained Earnings*				391.01	535.57	5102.51	5289.75	- 511
	54	Total shareholders' Ec	paity			\$181.82	\$226.67	\$242.51	\$329.76	531
	50	Total liabilities and shu	ercholders' Equity			\$284.50	\$1890.05	\$454.63	\$577.23	548

1

Ш

П

Ы.

H.

П

1 |

1

П n

	10. s	0 1	1.2.6.	 	1		L I	EK.	19		
					Year						
					1999	2000	2001	2002	3		
		Cath and cath equivalents			54.27	56.38	\$7.62	58.88	3		
		Accounts receivable*			\$20.54	\$24.39	\$28.77	584.11	-53		
BUSIN		Invertories"			526.73	\$39.45	336.75	543.27	53		
DUSIN		Defensed income taxes*	Ì		50.08	50.00	50.00	50.00	5		
		Total current assets	<b>.</b>		551.54	501.22	\$78.14	\$49.21	37		
PL/		Filos di assets									
	-41	Cost*			5331.64	\$421.92	2343.87	5543.24	545		
	44	Accumulated Depressintian*			298,72	5105.09	\$112.40	5122.25	511		
	41	Net fixed assess			\$272.92	5314.83	\$3191.47	\$491.07	353		
	44				\$0.00	59,00	\$0,00	\$0.00	- 3		
	-45	len			50.00	\$0.98	50.00	\$0.08	3		
	45	Other			50.08	50,00	\$6.00	50.04	- 5		
	-43	Total ass			\$284.50	\$380,85	\$464.61	\$\$37.23	564		
	AS Link	ilities .									
	-29	Accounts payeds			531.83	\$83.43	\$43.84	584,45	- 34		
	54	Current ristit*			\$30.84	\$43.00	\$64.85	\$79.49	1.1		
	51	Yotal current liabilities			562.69	2106.46	\$148.65	5173.90	.58		
	52	Long-term debt*			546.00	544,92	383.41	573.57	- 523		
	-51	Otherlong-term liabilities*			.50.68	59.80	\$6.00	59.08	5		
Prepared by:	44	Total liabilities			5102.69	\$153.36	\$292.10	5247.47	525		
Olson & Associates RO, Box 2240	1	reholders' equity									
Frederick, MD 21 T05		Section Shark	-tal*		599.00	\$1.50,50	\$150.00	5229,00	520		
12011 695-2500					391.01	596.67	5102.51	52895.78	511		
					18181.81	5226.67	5242.51	\$329.76	534		
	38	enolders' Equity			\$284.50	\$380.05	\$454.65	\$\$77.23	- 563		

# Plans are worthless, but planning is everything.\*

#### - Dwight D. Eisenhower

\* National Defense Executive Reserve Conference, Washington DC, November 14, 1957

## **Startups Search**

# **Companies Execute**

Memo: Larry Bossidy, <u>Execution – The Discipline of Getting Things Done (2002)</u> "Execution is a systematic way of exposing reality and acting on it." "Just get out there and build it; when you have something to play with . . . something tangible, that's when the real learning happens."

> Jack Dorsey Co-Founder, Twitter and Square Copenhagen Money 20/20 Conference (Monday, June 26, 2017)

# Instead of (*Before*) creating business plans...

# Today we discover business models.

# Investors, Grant Reviewers Our Customers, Stakeholders Need Us To

## **DISCOVER & VALIDATE**



Through **Discovery We** Engage so that we can develop an understanding of (their) needs, desires, behaviors, characteristics, beliefs, influences, motivations, (dimensions) . . .

"Excellent strategy, General...Though I fear the enemy might be full size..."

# **Qualitative Research**

<u>Talking to Humans,</u> Giff Constable (2014: 1<sup>st</sup> edition, V1.72, <u>Business Model Generation</u>, A. Ostervalder & Y. Pigneur (2010) <u>Value Proposition Design</u>, A. Ostervalder et a. (2014) <u>The Start-Up Owner's Manual</u> Steve Blank & Bob Dorf (2012)

# "Success starts with understanding your customers."

<u>Talking to Humans</u> Giff Constable © 2014 1<sup>st</sup> edition, V1.72

# "Seek First to Understand, then Seek to be Understood"

Stephen R. Covey, <u>The 7 Habits of Highly Effective People</u> https://www.stephencovey.com/7habits/7habits-habit5.php

#### Seek First To Understand, Then Seek To Be Understood\*



How We "Listen":

1. Ignore

2. Pretend

3. Be Selective


4. Be "Active"

Mimic (Rephrase or Reflect)


5. Be Empathic

\* Stephen Covey, The Seven Habits of Highly Effective People

#### Seek First To Understand, Then Seek To Be Understood\*



\* Stephen Covey, The Seven Habits of Highly Effective People



You've got to start with the customer experience and work back toward the technology - not the other way around.

(Steve Jobs)

### **Remember: Balance Your Vision w/ Reality**

**OPEN-**

MINDED

C<sup>3</sup>: Capable Credible Concerned

**NO BUY-IN** 

Do you really understand your customer(s)?

#### Rationalize Justify Confirm

Source: The Innovation Group (www.tigi.net)

**RE-CONFIRM** 


## **Business Model Generation** (Customer Discovery & Validation)


Alexander Osterwalder & Yves Pigneur, <u>Business Model Generation</u> (2010)


<b>B</b>	is a		$\mathbf{)}$	
	KCC MM	F12	[ h	HOW a company CREATES VALUE for
a Compo	nerts		JU	delivering produce or services for customers.
g Compo 7. KEY FART		1. VALUE TROPOSITIONS 4	CUSTOMER 2.	CUSTOMETS.
	6 KEY	3		SEGNENIS
	RESOURCES	5. REVENUE S		


TIONS 4. CUSTOMER 2. CUSTOMER 2. CUSTOMER 8. KEY ACTIVITIES 7. KEY PARTNERS THE LOGIC OF HOW WE WILL MAKE MONEY **Customers - Offer - Infrastructure - Financial** AKA HOW "THEY" WILL PROFIT 5. REVENUE STREAMS 9. COST STRUCTURE


## Before Trying to Sell . . . . . Customer Development












## Customer Segments and Customer Types


A <u>Customer Segment</u> is a subset of the marketplace that makes decisions in a defined way for a reason.

A <u>Customer Type</u> defines their role in the marketplace.

## **Customer Types**

- End User
- Influencer\*
- Recommender
- Economic Buyer/Payer
- Decision Maker
- Saboteur
- \* Remember William Dawes?






1. VALUE 1. PROPOSITIONS 4. CUSTOMER RELATIONSHIPS 2. CUSTOMER SEGMENTS 8. KEY ACTIVITIES 7. KEY FARTNERS START WITH A BLANK CANVAS 5. REVENUE STREAMS 9. COST STRUCTURE

## Launching the Canvas

## We begin with <u>Hypotheses</u> Also known as <u>Educated Guesses</u>





## Hypotheses -

#### My target customers will be . . .

The problem my customer wants to solve is . . .

My customer's need can be solved with . . .


My customer can't solve this today because . . .

The measurable outcome my customer wants to achieve is ...

My primary customer acquisition tactic will be ....

My earliest adopter will be . . . I will make money (revenue) by... My primary competition will be... I will beat my competitors primarily because... My biggest risk to financial viability is . . . My biggest technical risk is . . . The assumptions, if proven wrong, will cause business failure are . . .

Assumptions




# 2. Test Your Hypotheses


Identify Customer Problems and Needs

Test hypotheses about CS and VPs...

... Iterate and Pivot



NO SELLING! EXPLORE & DISCOVER ONLY



## **Talk to Strangers**

## Get Their Stories, not Speculation

Ask Open-Ended Questions



## The Art of Asking Questions . . .

I. EYES

2. HANDS

3. POSTURE

- 1. Closed v. Open-Ended
- 2. Controlling the Focus of conversations
- 3. Fact-Finding questions
- 4. Feeling-Finding questions
- 5. The Empathic Question
- 6. Avoid the Directive Question

#### ... & Finding the Hot Buttons


## **The Approach**

Watch for responses, reactions, body language

Discover the dominant buying motive (What emotions are you appealing to?

They won't tell you what it is

#### REMEMBER: GET THEM TO DO THE TALKING!




### Our Investors Want Us . . . To Understand Buyer Behavior

- 1) People don't care about our product or solution as much as we do (It really is about them).
- 2) They perceive innovation as risky and difficult.
- 3) They fear making mistakes.
- 4) It takes time: selling is building & maintaining a relationship.
- 5) Don't tell our buyer something that can be asked.

\*This includes Investors and Corporate Partner Executives: Be "Coachable" Source: Deanna Berg, Ed. D., "Ask, Don't Sell! Strategies for Selling Innovation"




I have a cool new tissue product for you!




My product is a disruptive innovation!

Get lost!



ACK!! What do you want? FINALLY!! I am glad you asked . . .



## **Cute Baby?** (Beware of Cognitive Bias)





## **Confirmation Bias**



# Where might our first customers come from?







interested in this

After 10, 25, 50, . . . 100 interviews,

What's our story (lessons learned; insights gained)?

## **Corporations, Partnerships, Alliances as Investors**

## **Alliances for Start-Up Ventures**



- Investment; Need for Cash
- Access or Partner with Technological Advances
- Find a Viable Solution for a Tough Problem
- Fend off a Competitor
- Gain Market Share . . .
- . . . and Motivate Other (More Risk-Averse) Investors

## Who To Target

#### **Feasible Partner**

- 1) Relevant Product Lines
- 2) Established Presence in the Market.

#### **Viable Partners**

- Good Financial Health
- Established in the Market with a Relevant Product Line
- Can Provide Capabilities Relevant for Commercialization
- Possess Good Absorptive Capacity

## **Match-Making Search Questions**

- 1) Name of Target and Relevant Unit
- 2) Current Customer Base
- 3) Target's Reason for Interest
- 4) **Prior Acquisition(s)** of Technology from the Outside
- 5) Criteria Likely to be Used to Evaluate Your Technology
- 6) Likely Information Desired
- 7) Likely Preferred Legal Structure for Deal
- 8) At What Stage in Maturity does the Target Prefer to Obtain Technology
- 9) Will Target Participate in Concurrent Engineering or Test & Evaluation?
   10) Who is the Ultimate Decision-Maker(s)






"Technology Niche Analysis"

National Institutes of Health

## **Analyze for Strategic Fit**


- **1) Return on Investment** (Their Market Share Our Market Access)
- 2) Your Mission Statement Goals
- 3) Management Capabilities; Their Intentions;
- 4) Corporate Culture; History of Partnerships
- 5) Business History, Financial Background
- 6) Partnership Strategic Direction

See: Larraine Segil, <u>Intelligent Business Alliances</u> (1996: Times Business, Random House)



"Stay with me now, people, because in step C, things get a bit delicate."

### Examine Closely Before Entering Into An Agreement



- Financial Situation
- Operations
- Market Presence
- Quality of Product or Service
- Views on Customers and Service
- Marketing
- Desire

http://www.va-interactive.com/inbusiness/editorial/bizdev/ibt/alliance.html

## **Check List**

- 1) Financial Situation
- 2) Annual Revenue
- 3) Annual Growth
- 4) Organization Structure

#### 5) Management Experience & Background

- 6) Market Presence
- 7) Prospect Markets
- 8) Growth Opportunities
- 9) Quality Standards
- 10) Customer Feedback

11) How Are Complaints Handled

12) Marketing

- 13) Cash & Personnel
- 14) Desire, Enthusiasm

# How To Approach a Prospect

#### The Deal That You Are Proposing Should be Equally As Beneficial To Them As It Is For You

\* Handle Similarly to an I-Corps Value Proposition

## Checklist to Formally Discuss with a Potential Partner

- 1) The Business Opportunity at Hand
- 2) Respective Financial Resources and Responsibilities
- 3) Steps Required to Launch Alliance &/or Develop The Product
- 4) Who Will Supply Which Personnel
- 5) Duration of Commitment or Relationship
- 6) Intellectual Property Ownership; Exit Strategy

### **Licensing** – "Wheelbarrow Expressions of Value"


- Lump-Sum License
- Royalty License
- Upfront Payment(s)
- Annual Payments
- Milestone Payments
- Option Payments
- Royalty Adjustments
- IP Rights
- Commitment to Purchase
- Equity





Source: Robert Goldscheider, Editor, <u>Licensing Best Practices</u> (2002: Wiley & Sons)


# Addendum


- I "Crossing the Chasm"
- II Investor Pitch Academy
- III Overviews
  - The Term Sheet: (a) Economic, (b) Control
  - The Capitalization Table
  - Convertible Debt
- IV Telling Our Story











- 1. Innovators
- 2. Early Adopters: Visionaries
- 3. Early Market: Early Majority
- 4. Later Market: Later Majority

#### 5. Laggards

Geoffrey A. Moore, <u>Crossing The Chasm</u>, 3<sup>rd</sup> Edition, 2014

### Distinguishable Sets of Prospective Customers

- For a given set of products/services; they present common, intrinsic needs & wants;
- each hears, responds differently to targeted messaging.
- They reference others in THEIR GROUP (not prior one) when buying-in

## Tech Enthusiast (Innovator)



#### **Notable Characteristics**

- 1. "Into" new tech products
- 2. Technology is a "central interest"
- 3. Seek them out pre-market; don't need to be fancy (early MVP)
- 4. Winning them over is key; they'll help debug
- 5. Their endorsement reassures other decision makers that the product does in fact work

"Give me the truth: no tricks – techie-to-techie interaction – Give me the new stuff, first . . . . . . and I want it cheap"

## Early Adopters (Visionaries)



#### They can make noise . . . . . . music to us

Geoffrey A. Moore, Crossing The Chasm, 3rd Edition, 2014

#### **Notable Characteristics**

- 1. Recent entrants in executive ranks; motivated; have a dream
- 2. Seeking Fundamental Breakthroughs; New World; "Order of Magnitude ROI
- 3. Want to be First; Champion, Risk-Taker; Change Agent & Be Recognized
- 4. Have a Budget; Not Afraid To Use It
- 5. Will authorize <u>and control</u> Pilot Projects, Phases, Milestones;

Measures/Metrics (Based on Their Needs; Not Yours)

6. In a Hurry: Windows of Opportunities, Deadline Pressures

## Early Market (Early Majority)



#### **Notable Characteristics**

- 1. Pragmatist, Prudent, Cautious
- 2. Not Assertive; Not Pioneering
- 3. Not the Stars of Show
- 4. Not Futuristic; Present Day
- 5. Value Experiences of Their Peers
- 6. Prefer Percentage Improvements

Bowling Pin Analogy: One pin knocks over others 
Prefer "Market Pull" to "Sales
Push" 
Want evidence of installations 
Don't Sell Them Disruption

Geoffrey A. Moore, <u>Crossing The Chasm</u>, 3<sup>rd</sup> Edition, 2014

### Later Market



Geoffrey A. Moore, <u>Crossing The Chasm</u>, 3<sup>rd</sup> Edition, 2014

#### **Notable Characteristics**

- 1. Conservative; Not interesting to Entrepreneurs
- 2. More Traditional than Pragmatists; not willing to work at the mastering the product
- 3. Prefer mature products; bugs removed; risks eliminated
- 4. Convenience, not performance
- 5. Costco buyers: pricing does not pay for tech support



#### EVOLUTION OF TEXT - BY H2M1 WWW.TOONDOO.COM KING THAMUS- BEHOLD YE MY NEW INVENTION: WRITING! IT SHALL IMPROVE THE WISDOM AND MEMORY OF THE PEOPLE! PRINT THE BIBLE? NO. THE MASSES WILL RECEIVE A NO. THEY WILL RECEIVE A QUNATITY OF INFORMATION QUANTITY OF INFORMATION WITHOUT PROPER INSTRUCTION. WITHOUT PROPER INSTRUCTION. AND THEY WILL BECOME A AND THEY WILL BECOME A INTERNET NO. IT WILL GIVE PEOPLE ACCESS BURDEN TO SOCIETY! BURDEN TO SOCIETY! TO A QUANTITY OF INFORMATION WITHOUT PROPER INSTRUCTION. AND THEY WILL BECOME A BURDEN TO SOCIETY!

Geoffrey A. Moore, Crossing The Chasm, 3<sup>rd</sup> Edition, 2014

# The Chasm



\* Geoffrey A. Moore, <u>Crossing The Chasm</u>, 3<sup>rd</sup> Edition, 2014

#### Establish a "Bounded" Market Segment

- **1**. Make your initial challenge simple
- 2. Focus on a very specific, confined niche market
- 3. Deliver an over-abundance of support
- 4. Develop your solid list of references,
  - collateral, and internal procedures
- 5. Concentrate communication

#### Don't Try to Expand Too Quickly

## War Analogy: Establish A Beachhead



#### Be Market-Driven; not Sales-Driven

Geoffrey A. Moore, <u>Crossing The Chasm</u>, 3<sup>rd</sup> Edition, 2014

- **1.** Objective: Get those References
- 2. Single very specific niche segment: drive word-of-mouth effect
- 3. Own that niche, when captured, as your next-niche entry point
- 4. Avoid the multi-opportunity "Sirens"
- 5. Pragmatists go for and fortify the market leaders. That's why they delay their decisions

# Addendum II: Investor Pitch Academy

## What Should We Tell Investors?

- I. "Elevator Drill" Set The Stage and Establish Expectations; Five (5) "Take-aways"
- II. What is the problem?
- **III.What is Your Solution?**
- IV.Business Model: Define Your Market; Customer Segment(s) – "Pains", Needs; Desired Gains
- V. Value Proposition

## ... and

- VI. Competition Your Distinguishing Characteristics
- VII. Market Development ("Get Keep Grow") Plan
  - Sales/Distribution; Revenue Stream/Tactics
- VIII. Your Team
- IX. Pro Forma Financial Statement
- X. Corporate Development Timeline

## ... Finally


- XI. Capital Funds Required Use of Funds
- XII. Exit Strategy
- XIII. The Deal
- XIV.Final Summary Slide (See Slide I)
- XV. Back-Up Slides

# **How Many Slides?**

- 1) How much time do you have? 3-6-12-18
- 2) Keep it Moving
- 3) Simple is Good
- 4) No Sentences; Few Words
- 5) White Space = Good

# What is (Company)? Too Much

- <u>A recurrent service revenue company, predicated on telemedicine and novel</u> <u>neuroimaging devices</u>
- That transforms existing acute/preventative stroke and TBI diagnosis/treatment paradigms by:
- Delivering neurological diagnosis upon *initial patient contact. ANYWHERE*
- Changing the process and logistics of care
- Reducing service time
- Providing seamless continuum of care from home to hospital
- Fostering earlier and appropriate and warranted therapy and reduced costs
- Improved morbidity and mortality
- Significant Investment return for investors with recurrent revenue based on established CPT codes



# The Issue: Diagnosing Traumatic Brain Injury & Stroke

- Strokes: \$74B cost per year in U.S. \$130B by 2030
- Traumatic Brain Injury (TBI): \$60B cost per year in U.S.

Blend 6 & 7 into a Pain – Need Slide: Critical Problems that Mandate Resolution: Process, Outcomes, Cost to Patient & Society

- $\rightarrow$  Keys to reducing costs:
  - Diagnosis and prevention pre-stroke
  - Rapid diagnosis and treatment post-stroke and post-TBI
  - Reduction in severity of acute stroke and TBI



Stroke : Time lost is brain lost


#### Company's system is the unique solution

# (Still) Too Crowded



- Stroke: 880,000/Year; US
- \$70B/Year
- \$ 130B (2030)
- \$140,000/episode
- \$300-800,000 if severe
- Traumatic Brain Injuries (TBI): 1.7 M/Year
- >\$100B/Year

#### **Stroke: Time Lost = Brain Lost**



- 300,000/ Year
   60-80% die/severe disability
- Only 10% (27,000) definitive early treatment

Early Diagnosis, Early Treatment


Significant Revenue

### Better



### 2 Million Neurons per Minute

#### **Time Lost is Brain Lost**



880,000 \$70 B \$140 - \$800K 10%

## **The Elevator Introduction**



Who


What

Why

How

## **The Problem**

What is it? Who has it? How badly do they want it fixed? What have they tried so far? Repercussions - Ramifications



# Make Us Care

# **Your Solution**

- 1) What is it? Simple, not in Detail
- 2) What it does? <u>NOT how it does</u>.
- 3) What will happen if it is implemented?
- 4) How much will it save?
- 5) What will it allow your customer to do that couldn't be done before?




## **For Whom?**







How Significant? How Large? Scalable? How are you **Positioned? Beachhead?** 

## **Value Proposition**






### Market Development: Get, Keep & Grow



## **Sales Channels**



## **Revenue Stream**

**Asset Sale Usage Fee Subscription** Fees Rent, Lease License Brokerage Advertising

**Fixed Menu Pricing List Price Product Feature Dependent Customer Segment Dependent Volume Dependent Dynamic Pricing Negotiation Yield Management Real Time Market Auctions** 

# Your Team



Yiying Lu CEO

Joe Gebbia CPO

### IMPRESS US



Tobias Van Schneider Art Director



Arash Ferdowsi CTO



Dave Altarescu Director of Marketing



Paige Brewster Account Manager

#### Experience & Credentials

Advisors & Investors



Paul Graham Advisor



Brian Chesky Creative Advisor



**Jason Jones** 

Investor



Tim Ferriss Investor


### **Financial Proforma**

(\$000's)	2016	2017	2018	2019	2020	2021
Revenue Units Sold Gross Profit	\$43 251 (208)	\$3,032 2,458 574	\$11,900 5,208 6,692	\$57,245 16,217 41,028	\$112,881 22,939 89,942	\$192,721 32,425 160,296
Gross Margin Sales/Market/Admin R & D EBITDA	(482%) 707 - (\$015)	19% 2,305 1,200	56% 7,609 1,350	72% 19,948 2,050	80% 34,756 3,050	83% 46,877 5,050
Capital Funds Cumm. Net Cash Customer Events	(\$915) \$1,000 \$84 125	(\$2,930) \$3,000 \$155	(\$2,267) \$3,000 \$887	\$26,030 - \$19,917	\$52,135 - \$79,053	\$108,368 - \$187,421
Net \$/Event Venues/Sites Cost/Venue	\$285 5 \$37	5,500 \$536 50 \$34	20,500 \$566 150 \$28	98,250 \$572 500 \$27	192,750 \$575 700 \$27	327,750 \$577 1,000 \$27


### **Financial Proforma - Simplified**

	Units Sold 251 2,458 5,208 16,217 22,939 32,425	Units Sold       251       2,458       5,208       16,217       22,939       32,425         EBITDA Capital Funds       (\$915)       (\$2,930)       (\$2,267)       \$26,030       \$52,135       \$108,36         -       -       -       -       -       -       -	(\$000's)	2016	2017	2018	2019	2020	2021
	Units Sold 251 2,458 5,208 16,217 22,939 32,425 EBITDA (\$915) (\$2,930) (\$2,267) \$26,030 \$52,135 \$108,36	Units Sold       251       2,458       5,208       16,217       22,939       32,425         EBITDA Capital Funds       (\$915)       (\$2,930)       (\$2,267)       \$26,030       \$52,135       \$108,36         -       -       -       -       -       -       -	Revenue	\$43	\$3.032	\$11 900	\$57 245	\$112 881	\$197.77
		Capital Funds \$1,000 \$3,000 \$3,000							32,425
Net \$/Event \$285 \$536 \$566 \$572 \$575 \$57	Net \$/Event \$285 \$536 \$566 \$572 \$575 \$577	Venues/Sites 5 50 150 500 700 1.000	Capital Funds Customer Events Net \$/Event	\$1,000 125 \$285	\$3,000	\$3,000	- 98,250	192,750	\$108,36 - 327,750 \$577

## **Corporate Development Timeline**



# **Funds Required – Use of Funds**



# Your Exit Strategy

**BNP PARIBAS** Roche SANOFI Who? Why? **Recent Deal History;** Structure/Value/Multiple

- 1) Strategic Acquisition
- 2) Competitor Acquisition
- 3) Initial Public Offering (IPO)
- 4) Management Buy-Out
- 5) Investor Buy-Out

### The Deal

#### Almost Always Disagreements; be Open-Minded

- 1) Typically: (1) Straight Equity; (2) Convertible Note
- 2) Don't add \$ valuation to the slide . . .. . . prepare to discuss a range
- 1) % Percentage of start-up

# **The Close**

#### Reminder of Key Points

#### Prompts to ask questions during Q&A

Source: Rockies Venture Club



## **Back Pocket/Appendix Slides:**

- Included in your deck for AFTER the pitch, during Q&A
- Something not conveyed during pitch
  - OR to support something in more detail
- Examples:
  - Extended Info on Competition
  - Expanded Pro Forma



- Further Explanation/Display of Product or Technology
- "Comps", Intellectual Property

# Addendum III: The Term Sheet Capitalization Table

# Two Key Things That Matter in Term Sheets: Economics & Control

## How Much Are You Raising?

- 1) Determines who you will speak to
- 2) Complex Financial Models: We know that they are wrong
- 3) Focus more on the length of time for funding to get to meaningful milestones
  - How long to ship your first product?
  - Time to get to a certain # of users or specific \$ amount
  - Monthly spend: burn rate/number of key personnel
  - Think balance sheet; working capital; cushion for reality

### **Don't Ask For Too Much Either**

- 1) For example, if you need \$500,000 but are looking for \$1.0 MM . . .
  - Q: How much money do you have committed to the round?
  - A1: I have \$250,000 raised (of \$1.0 MM sought), or
  - A2: I'm at \$400,000 on a \$500,000 raise and we have room for one or two more investors
- 2) Don't go for a range e.g. \$5 MM to \$7 MM
- 3) Know what you need the funds for

### **Fundraising Materials**

- 1) "Fast Facts" (Not the same as the Elevator Pitch)
- 2) Executive Summary
- 3) Presentation (Pitch Deck) See Addendum I
- 4) Later Stage: Business Plan
- 5) Later Stage: Private Placement Memorandum (PPM)

While style does count, don't overdesign; substance matters the most (Focus on Content)

### Clear, Concise, Interesting & Easy to Process

If you have to talk us through everything or respond to a lot of clarification questions, you have lost the battle before you've started.

### **"Fast Facts" – Single Page**

#### Company, Logo, Product Name

Problem StatementLetGraphicIOpportunity/SolutionLet(Distinguishing Value)AMarket/Target AudienceRaisFounders/TeamCo

Leadership

Advisors

Legal Counsel

Accountant

Raise (\$), Stage

Contact Info

### **Executive Summary**

- 1) One Three Pages
- 2) Idea, Product, Team, Business
- 3) For Example:
  - Business Concept
  - Market Opportunity/Problem Solved
  - Product Offering/Technology (Graphic)
  - (Clinical/Regulatory Pathway)
  - Intellectual Property Status
  - Business Model/Strategy
  - Competitive Advantage(s)
  - ProForma
  - Competition/Market Circumstances

- Founders/Team
- Leading Advisors
- (Legal Counsel)
- (Accounting)
- Timeline &
- Key Milestones
- Financial Offering
- Use of Funds

## Your Presentation (Pitch)

- 1) See Addendum I
- 2) Customized to Meeting or Event
- 3) Ten to 20 Slides
  - PLAN TO GO SLOWLY 1 Minute +/Slide\*
  - Same Info as Executive Summary
  - Focus on Substance (but visually appealing)
  - Again: Clear, Concise, Interesting, Easy to Process

### Also

- 1) Business Plan Still Useful\*
- 2) Private Placement Memorandum
- 3) Detailed Financial Model
  - Expense Side is instructive in re how you think
  - Assumptions underlying revenue forecast
  - Monthly Burn rate/cash consumption
  - Focus on lagging cash spend increase behind planned revenue growth

\* Think about the Lean Startup Business Model/Canvas and Discovery/Validation Method

#### **Due Diligence Material\***

- 1) Capitalization Table
- 2) Contracts
- 3) Material Agreements
- 4) Employment Agreements
- 5) Board Meeting Minutes

\*See "Resources at www.venturedeals.com

#### **A Few More Notes**

"If you want money, ask for advice."

"Do your homework. . . If someone insists that we sign an NDA before we review a plan, we know that they did absolutely zero research on our firm or us. At best the submission doesn't rise to the top; at worst it is ignored."

#### **A Few Thoughts on the Term Sheet**

- 1) Entrepreneur's Perspective: "Think of it as a Blueprint for your Future Relationship with Your Investor."<sup>1</sup>
- 2) Key Concepts: Economics and Control
  - Economics Return from a Liquidity Event
  - Control Mechanics allowing affirmative exercise over the business or veto decisions
  - Important things to pay attention to: "They rule the day."

Feld, Mendelson, <u>Venture Deals</u> (2016); Ramsinghani, <u>The Business of Venture Capital</u> (2014)

### **Economic Terms**

- 1) Price
- 2) Liquidation Preference
- 3) Pay-to-Play
- 4) Vesting
- 5) Employee Pool
- 6) Anti-dilution

#### Price

Usually, this - Price: \$ \_\_\_\_ per share (original purchase price) – fully diluted pre-money valuation of \$ \_\_\_\_ million and fully diluted post-money valuation of \_\_\_\_ million....assumes the conversion of all outstanding preferred stock ...

Or this - Amount of Financing: An aggregate of \$ \_\_\_\_\_ million, representing a \_\_\_\_% ownership position on a fully diluted basis

Be certain you know what "*pre-money*" and "*post-money*" mean as well as "*fully diluted*" (referring to *employee or options pool*).

#### **The Matter of Options**

- 1) Size of the pool is taken into account in the valuation of the company
  - VC may want option pool as large as possible. Come armed with a detailed option budget regarding planned hires, next financing date, approximate option grant to land each hire
- 2) Warrants right purchase a certain number of shares at a predetermine price.
- 3) Bridge loan existing investor provides funds at a convertible debt (converts to equity) with a discount on the equity rice

#### **How do VCs Value Companies**

- 1) Stage of the company
- 2) Competition with other funding sources
- 3) Experience of the Entrepreneur
- 4) Size & Trendiness of the Market
- 5) VC's natural entry point
- 6) The numbers
- 7) Prevailing economic climate

### **Liquidation Preference**

- 1) Impacts how the proceeds are shared
- 2) Actual Preference: A certain multiple (generally 1X) of the original investment per share is returned to the investor(holder of Series A Preferred) before the common stock receives consideration
- 3) Participation
  - Full Receipt of liquidation preference, then share the rest
  - Capped Receipt, then share up to a certain multiple
  - No Receipt, but no sharing thereafter

#### **Examples: Four Scenarios\***

- 1) Preferred Series A, 1X Liquidation Preference, No Participation
- 2) Preferred Series A, 2X Liquidation Preference, No Participation
- 3) Preferred Series A, 1X Liquidation Preference, Full Participation (No Cap)
- 4) Preferred Series A, 1X Liquidation Preference, Participation up to 3X Cap

\* See Brad Feld and Jason Mendelson, <u>Venture Deals</u> (2016), pp. 45 – 53, for a full treatise on this topic with numerous scenarios and mathematics

#### **Example I**

- One round of financing at \$5.0 MM Series A at a \$10 MM pre-money valuation
- So, post-money valuation = \$15 MM; investors own 33.3%
- WHAT IF: Company has a \$15 MM offer?
  - 1X Liquidation Preference (LP), No Participation: 1X LP = \$5.0 MM, but so does converting to common at 33.3% & taking the proceeds that way.

#### Example II (Same Offer)

- One round of financing at \$5.0 MM Series A at a \$10 MM pre-money valuation
- So, post-money valuation = \$15 MM; investors own 33.3%
- WHAT IF: Company has a \$15 MM offer?
  - 2) 2X Liquidation Preference (LP), No Participation: 2X LP
     = \$10.0 MM while converting to common at 33.3%
     results in \$5.0 MM. So, take the LP.

#### Example III (Same Offer)

- One round of financing at \$5.0 MM Series A at a \$10 MM pre-money valuation
- So, post-money valuation = \$15 MM; investors own 33.3%
- WHAT IF: Company has a \$15 MM offer?
  - 3) 1X Liquidation Preference, Full Participation (No Cap):
     1X LP = \$5.0 MM, while participating at 33.3% for the remaining \$10.0 MM (= \$3.3 MM). Total = \$8.3 MM

#### Example IV (Same Offer)

- One round of financing at \$5.0 MM Series A at a \$10 MM pre-money valuation
- So, post-money valuation = \$15 MM; investors own 33.3%
- WHAT IF: Company has a \$15 MM offer?
  - 4) 1X Liquidation Preference, Participation up to 3X Cap: 1X LP = \$5.0 MM, while participating at 33.3% for the remaining \$10.0 MM (= \$3.3 MM). Total = \$8.3 MM, same as Example III.

### Pay-to-Play

#### 1) Usually relevant in down round financing

- Company is struggling & needs another financing
- In the event of a Qualified Financing, shares of Preferred A held by an investor who does not participate in this round is converted to Common Stock
- 2) Generally considered good for the company and its investors
  - Ensures that all investors agree in advance to the rules of the engagement concerning future financings

## Vesting

- 1) Typically stock & options vest over four years
- 2) Usually 25% at end of Year 1 (the "cliff"); remaining 75% over 36 months
- 3) If you leave before the end of four years, the vesting formula applies & you get only a percentage of your stock
- 4) Founders may get their 25% at close of financing

### **The Employee Pool**

- 1) Aka the "Option Pool"
- 2) Reserved for future issuance
- 3) Clarifies the capital structure & defines allocation %
- 4) Is redundant with the attached capitalization table, but manages possible confusion
- 5) VCs may want to inflate the pool

### **Anti-Dilution**

- Used to protect investors in the event a company issues equity at a lower valuation than in previous rounds.
  - Ratchet-based, or
  - Weighted average

### **Control Terms**

1) Board of Directors

- 2) Protective Provisions
- 3) Drag-Along Rights
- 4) Conversion

# **Board of Directors**

#### Think carefully about proper balance

	Early Stage (5 Members)			
<u>Early Stage (3 Members)</u>	Founder			
Founder/CEO	CEO			
VC/Angel	VC/Angel			
Outside Member (or Other Founder)	2 <sup>nd</sup> VC/Angel			
	Outside Member			

- More mature board count is 7 9
- Outside member compensation: options (0.25% -0.50%, vested 2 4 years)
- Outside members invited to invest
- Instead of founder or investor control, protective provisions preferred

## **Protective Provisions**

Effectively veto rights on certain actions (generally standardized)

- 1) Change terms of stock ownership
- 2) Authorize creation of more stock
- 3) Issue stock senior or equal to VC's
- 4) Buy back common stock
- 5) Sell the company
- 6) Change certificate of incorporation or bylaws
- 7) Change board size
- 8) Pay or declare a dividend
- 9) Borrow money
- 10) Declare bankruptcy
- 11) License away IP; effectively selling company

# **Some Thoughts**

- Materiality Qualifiers (e.g. changing terms of rights, privileges, preferences of preferred stock; authorized number of shares; certificate of incorporation or bylaws
  - Go for specificity rather than reasonableness (words such as "material" " or "materially"); avoid the debate on what "material" means
- What about provisions for future rounds?
  - Series B gets its own protective provisions

— Go along with original investors as a single class\*

\* As long your Cap Table is rational, things should be fine; keep your investors aligned

# **Drag-Along Agreement**

Generally two types:

- Preferred shareholders "drag-along" the common (often regarding the sale of the company)
  - Small investors may want to go along with majority of common shareholders instead
- Departed founder cannot play "hold-out" on voting matters

### Conversion

Preferred shareholders have the right – at any time - to convert to shares of common stock.

Automatic Conversion (specified applicable conversion price) – in the event of an IPO\*

\* Regardless of thresholds, you should not allow investors to negotiate different automatic conversion terms

# **Capitalization Table**

		COMPANY					
	C	APITALIZATI	ONTABLE				
	Number of Shares	Original Issue Date	Price Per Share	Total Purchase Price	% of Class	% of Issued Shares	Fully Diluted % of Ownership
Founder Common Shares:							
Name			\$0.0001	0.00	NA	NA	NA
Name			\$0.0001	0.00	NA	NA	NA
Name			\$0.0001	0.00	NA	NA	NA
Name			\$0.0001	0.00	NA	NA	NA
nume.			90.0001	0.00	1071	inter a	101
Name	-		\$0.0001	0.00	NA	NA	NA
Name	-		\$0.0001	0.00	NA	NA	NA
Name	-		\$0.0001	0.00	NA	NA	NA
Name	-		\$0.0001	0.00	NA	NA	NA
Name	-		\$0.0001	0.00	NA	NA	NA
Total Common Shares	-		\$0.0001	\$0	0.00%	0.00%	0.00%
Preferred Shares - SEED							
	-		\$0.50	0	NA	NA	NA
	-		\$0.50	0	NA	NA	NA
	-		\$0.50	0	NA	NA	NA
Total Preferred Shares - SEED	-		\$0.50	\$0	0.00%	0.00%	0.00%
Preferred Shares - SERIES A							
			\$5.00		NA	NA	NA
			\$5.00		NA	NA	NA
			\$5.00		NA	NA	NA
Total Preferred Shares - SERIES A			\$5.00		0.00%	0.00%	0.00%
Total Preferred Shares' Series A			<i>\$</i> 3.00		0.0070	0.00%	0.0070
Preferred Shares - SERIES B							
Telefice shares series s			\$0.00	0	NA	NA	NA
			\$0.00	0	NA	NA	NA
			\$0.00	0	NA	NA	NA
Total Preferred Shares - SERIES B			\$0.00	\$0	0.00%	0.00%	0.00%
Total Preferred Shares - SERIES B	-		ŞU.UU	50	0.00%	0.00%	0.00%
TOTAL SHARES ISSUED				\$0		0.00%	0.00%
TOTAL SHARES ISSUED	-			50		0.00%	0.00%
Covertible Loan Shares - Common/Preferred							NA
Optional Reserve Convertible Loan Shares							NA
Total Common	-		\$2.50	\$-			0.00%
Restricted Common Stock Employees							NA
Total Restricted Stock - Vesting			\$2.50	\$ -			0.00%
Stock Options							
Stock Option Plan Reserved Shares							NA
Options Available for Grant	0						NA
Total Available Option Pool	0						NA
TOTAL CONVERTIBLE SECURITIES				\$-			NA
TOTAL FULLY DILUTED EQUITY							
Shares Authorized by Articles of Incorporation							
Common Stock							
Preferred Stock							

- 1) How does a typical capitalization table work?
- 2) Summarize who owns what part of your company before and after financing
- 3) What will I own if someone or an entity invests X% in my company at a Y valuation?

 Template Available (mkleckner@cox.net)

# A Simple Example


Class	Shares	<b>Preferred Price</b>	Valuation	Percentage
Founders	2,000,000	-	-	Α
Employee Pool	В	-	-	20%
Investors	С	D	\$5.0 MM	33-33%
TOTAL	E	D	\$15.0 MM	100.0%

- 1) 2 million shares held by founders before investment
- 2) \$10 million pre-money valuation; \$5 million invested
- 3) Post-money valuation = ? (\$15,000,000)
- 4) IF new employee option pool = 20% (post money basis; unallocated after investment
- 5) A = ? What is the Total Shares amount (E)? (2,000,000/A = 4,285,408)
- 6) B = E \* 0.20 = 857,081
- 7) C = E \* 33.3% = 1,428,326
- 8) D = \$5,000,000/1,428,326 = \$3.50 per share


# Addendum IV: Telling Our Story

# Your Story: The Hero's Journey

### **Behind Every Innovation is a Great Story**



## **Your Story Matters**



How important are those customer interviews?

### Why do our Stories Matter? Brain Science: Insula

#### Dopamine (Hope/Optimism)

### Cortisol (Stress)

### Oxytocin (Connection/Empathy)

# "Get Out of the Building!" Get Proof/Evidence. Discover and Validate!

Martin Kleckner III PhD MBA, Advisor University of San Diego BRINK SBDC 1 (619) 892-2565 mkleckner@cox.net

